Albumin News and Research

RSS

Skipping nightly toothbrushing could heighten cardiovascular disease risk

Research investigated the impact of toothbrushing timing on cardiovascular disease risk. The study found that brushing teeth at night was associated with lower cardiovascular disease risk compared to not brushing at all.

2 Jul 2023

Albumedix enters into collaboration agreement with Cell and Gene Therapy Catapult

Albumedix Ltd., an enabler of advanced therapies and the world leader in recombinant human albumin (rAlb), announced today that they have entered into a collaboration agreement with Cell and Gene Therapy Catapult (CGT Catapult) to investigate the use of Albumedix´ proprietary albumin-based solutions for advanced therapy applications, including viral vectors manufacturing.

From Albumedix Ltd. 29 Jun 2023

Albumedix and Valneva expand collaboration to include newly approved inactivated COVID-19 vaccine

Albumedix Ltd., a recognized global leader in Recombinant Human Albumin (rHA), specializing in the enablement of advanced therapies and biopharmaceuticals, today announces the expansion of its existing collaboration with Valneva SE, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need.

From Albumedix Ltd. 29 Jun 2023

Study finds new way to predict therapy response in metastatic renal cell carcinoma

Dr. Niklas Klümper, resident at the Department of Urology and Pediatric Urology of the University Hospital Bonn (UKB) and working group leader at the Institute for Experimental Oncology (IEO), and Dr. Jonas Saal, resident at the Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology of the UKB, demonstrated a significant improvement in predicting the response to therapy in metastatic renal cell carcinoma by incorporating the level of inflammation, which was assessed using two straightforward blood parameters, alongside the conventional imaging-based approach.

22 Jun 2023

Meat-free minerals: the mineral content, bioaccessibility, and bioavailability of iron and zinc vegetarian and vegan burgers

Researchers compared the mineral content and absorption of plant-based meat-free (vegan and vegetarian) burgers and beef burgers.

15 Jun 2023

Study shows how blood makes the brain’s immune cells toxic

In patients with neurological diseases like Alzheimer's disease and multiple sclerosis, immune cells in the brain known as microglia that normally fulfill beneficial functions become harmful to neurons, leading to cognitive dysfunction and motor impairment.

8 Jun 2023

Is there radiographic evidence of premature brain aging in individuals with type 1 diabetes?

Researchers identified brain regions most affected in middle-aged and older adults with type I diabetes.

6 Jun 2023

DIALIVE device may be a disease-modifying therapy for patients with acute-on-chronic liver failure

Acute-on-chronic liver failure (ACLF) occurs in 30% of hospitalized cirrhosis patients, leading to over one million deaths worldwide each year.

31 May 2023

First-in-human clinical trial of liver dialysis device successfully completed

The first successful in-patient trial of liver dialysis* has been completed by researchers from UCL, the Royal Free Hospital, UCL spin-out Yaqrit and their collaborators.

31 May 2023

Mutated gene protects the kidney from hypertension-induced damage

A mutation that causes severe hypertension also protects the kidneys from being damaged, reports a team led by Enno Klußmann of the Max Delbrück Center and the DZHK in "Kidney International".

30 May 2023

Do glucose-lowering medications have different effects on kidney outcomes?

Researchers evaluated the kidney outcomes in individuals with type 2 diabetes.

26 May 2023

The antimicrobial potential of nanoparticles

Nanoparticles have widely been used as advanced tools for the diagnosis, prevention, and treatment of infectious diseases.

23 May 2023

Long-term ketogenic diet boosts survival rates in advanced cancer patients

Long-term ketogenic diet shows improved survival rates in cancer patients, with a significantly better overall survival for those following the diet for ≥12 months. Promising results for cancer therapy.

18 May 2023

Malnutrition looms over Japan's 'Cinderella weight' women: Study warns of health risks

Study aimed to determine the nutritional status of young women at "Cinderella weight" in Japan. The results showed that underweight women had lower handgrip strength, cholesterol levels, and lymphocyte count and were prone to malnutrition due to low dietary diversity and deficiencies in various vitamins and minerals.

9 May 2023

Study shows MPXV can persist on surfaces for extended periods, but can be inactivated by alcohol-based disinfectants

Researcher evaluates the stability of monkeypox virus (MPXV) on stainless steel surfaces stored at different temperatures and using different interfering substances to mimic environmental contamination.

7 May 2023

Small vesicles released by intestinal bacteria induce immune activation and progression of liver cirrhosis

Researchers from Niigata University and Kyoto Prefectural University have revealed that small vesicles, around 100 nm in size, released by intestinal bacteria induce immune activation and progression of liver cirrhosis, as well as reduction of serum albumin level, subsequently leading to edema and ascites.

19 Apr 2023

Study finds human surfactant protein A can inhibit SARS-CoV-2 infectivity

Researchers assess the efficacy of the human surfactant protein A against SARS-CoV-2 infectivity.

10 Apr 2023

Red blood cell hitch-hiking facilitates SARS-CoV-2 multi-organ spread

Researchers assessed the infectious capacity of severe acute respiratory syndrome coronavirus 2 in plasma and red blood cells.

3 Apr 2023

Higher plasma caffeine concentrations might reduce body fat and type 2 diabetes risk

In a recent study published in the journal BMJ Medicine, researchers in the United Kingdom and Sweden investigated the probable causality of long-term serum caffeine concentrations on type 2 diabetes (T2D), adiposity, and major cardiovascular diseases (CVDs).

22 Mar 2023

Albumedix and Heartseed announce Recombumin® as a critical excipient in the manufacture of Heartseed's HS-001 investigational cell therapy as its first in-human trial commences

Albumedix Ltd, Nottingham, United Kingdom, now part of the global life science group Sartorius, and Heartseed Inc ('Heartseed'), Tokyo, Japan, Tuesday 14th March 2023, announce that Recombumin® is a critical component of Heartseed's HS-001, an investigational cardiac remuscularization cell therapy which has commenced first in human dosing.

From Albumedix Ltd. 16 Mar 2023